Dr. Ansell on Promise With Immunotherapy in Hodgkin Lymphoma

Stephen M. Ansell, MD, PhD
Published: Thursday, Dec 22, 2016



Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses studies exploring PD-1 inhibitors in Hodgkin lymphoma, specifically nivolumab (Opdivo) in the CheckMate-039 trial.

One of the main questions surrounding early data is whether the responses and promising results will hold up in longer follow-up, Ansell explains. Examples of more mature follow-up were seen at the 2016 ASH Annual Meeting. Moreover, the responses seen with the PD-1 inhibitors such as pembrolizumab (Keytruda) and nivolumab are showing response rates of 65% to 70% that are durable. Patients remain on treatment for 1 year, and sometimes 2 years, and are still benefitting from therapy.

These updated findings suggest that the responses are lasting longer and are more durable than previously thought, he adds.


Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses studies exploring PD-1 inhibitors in Hodgkin lymphoma, specifically nivolumab (Opdivo) in the CheckMate-039 trial.

One of the main questions surrounding early data is whether the responses and promising results will hold up in longer follow-up, Ansell explains. Examples of more mature follow-up were seen at the 2016 ASH Annual Meeting. Moreover, the responses seen with the PD-1 inhibitors such as pembrolizumab (Keytruda) and nivolumab are showing response rates of 65% to 70% that are durable. Patients remain on treatment for 1 year, and sometimes 2 years, and are still benefitting from therapy.

These updated findings suggest that the responses are lasting longer and are more durable than previously thought, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x